Noah Frydenlund

Urologic Oncology Fellow @UrologyMSK | @NM_urology, @iowamed, @umich alum | Ranking member of The Brothers Frydenlund

[Uromigos @Uromigos]

Uromigos Unsung Hero poster award! We discussed some pre-and post EV tissue data showing alterations in nectin-4 localization and expression. Possible implication for mechanisms of resistance! @OncoAlert

[UrologyMSK @UrologyMSK]

Congrats to our @SUO_YUO fellows @BeckySagerMDPhD (Modeling the effects of HIF2α inhibition on the ccRCC tumor microenvironment) and @aghasemzadeh1 (Understanding the Tumor Microenvironment in Non-muscle Invasive Bladder Cancer)
For their @ASCO YIAs!
https://t.co/KtAs3qBqXr

[Joshua Meeks @JoshMeeks]

@eugene_pietzak incrediblely elegant P2 on bcg + Pembro in VHR T1. 92% response, 94% RC- free. 1 early death and 21% iAEs. n=37 but great job to consider risk - based strategy. #AUA26

[MSK Department of Medicine @MSK_DeptOfMed]

Tomorrow at #AUA26, @eugene_pietzak will present data on combining pembrolizumab + BCG in patients with BCG-naïve very high-risk T1 non-muscle invasive #BladderCancer traditionally recommended for radical cystectomy.

10:50 a.m. ET in Hall D.

@AmerUrological @MSKCancerCenter

Session details: https://t.co/aV8knyP7e2

[Noah Frydenlund @NFryden]

Highly recommend this course to trainees. Performing a quality TURBT is an undepreciated skill that has major implications for our patients. The models are exceptional! @Olympus_Corp @JoshMeeks @bbmdmsk

[Joshua Meeks @JoshMeeks]

Another great course. Thanks to all our attendees, faculty and staff. @Olympus_Corp

[Noah Frydenlund @NFryden]

@ryansteinbergmd @LauraBukavinaMD @AnnahVollstedt @mvankuikenmd @KatherineAminMD @HenryLaiMD Ingest pathogenic bacteria, bacteria pass through GI tract and are present in stool, this leads to changes in perineal microbiome, bacteria seed GU tract from there?

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

Alliance researcher @eugene_pietzak @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG, a trial evaluating a two-step treatment approach for pts w/BCG-unresponsive non–muscle-invasive #bladdercancerome. Learn more: https://t.co/mjpt3I0t2n #NCI #NCTN #CancerResearch #NMIBC

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

The future of bladder cancer is in great hands. 👏

Stellar class of 2025 John Quale Travel Fellows!
@BladderCancerUS #BCANTT25

[NM Urology @NM_Urology]

Last week, James Eastham, MD, FACS, Urologic Surgeon at @MSKCancerCenter, joined the @NorthwesternMed Urology Chief Residents for a Lakeside Chat.

[NM Urology @NM_Urology]

The white coats are on and Residency has started! Congratulations to our interns! #Urologist #NMBetter 🥼

[UrologyMSK @UrologyMSK]

Congratulations to all the @UroOnc matches today. A special congratulations to our newest class!!

[Noah Frydenlund @NFryden]

Grateful for the amazing mentorship and support @JoshMeeks. True privilege to train @NM_Urology which has given me such a strong foundation to build on going forward. Excited for the next adventure! @EricLiUro @EdwardSchaeffer @UrologyMSK @UroOnc

[Joshua Meeks @JoshMeeks]

So proud of our residents matching into @SUO_YUO fellowships. @EricLiUro to @MayoUrology and @NFryden to @UrologyMSK. Awesome match. @NM_Urology

[Noah Frydenlund @NFryden]

Proud to see our work in the @JoshMeeks lab highlighted by @jitcancer. Check it out! @NM_Urology @NU_BMG_SQE

[Journal for ImmunoTherapy of Cancer @jitcancer]

Here is a closer look at recent #JITC article “Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer” by @NFryden, Khyati Meghani, @bonnie_choy & @JoshMeeks, from @NM_Urology & @NU_BMG_SQE. 1/10

[NM Urology @NM_Urology]

In @_backtableUro's podcast episode, Dr. @EdwardSchaeffer, department chair of #urology at @NUFeinbergMed, discusses precision medicine in prostate cancer with Dr. @AdityaBagrodia.
@UroOnc @DrAdamMurphy @ashleyrossmdphd @HitenDPatel @LurieCancer https://t.co/5XkuW0NKI3

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC short report: Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer https://t.co/coH7Mp3lxR @NFryden @bonnie_choy @JoshMeeks

[Amy Krambeck @amy_krambeck]

603.02 grams - final dry pathology report. Catheter out in < 12 hours and no transfusion despite preop admission for intractable hematuria. Bladder stone was also removed at time of enucleation. 100% endoscopic. #HoLEP @EndourologyNm @NM_Urology

[Noah Frydenlund @NFryden]

RIP. Trips to DMV were slightly less terrible because I had an excuse to visit one of my favorite buildings in the city.

[Architectural Icons @Archi_icons]

Iv been in love with, & mesmerized by the Thompson Center since I was a child. The most important postmodern public building in the world by far, it is an incomparably complex, virtuoso & ambitious symphony of geometry, polychromy, structure, space & ornament…

[Noah Frydenlund @NFryden]

@doctorjakeuro @OperateZen I started a mindfulness meditation practice last year with the @wakingup app. Has totally transformed my relationship with thought and ability to manage emotions. Always trying to improve.

[YUO @SUO_YUO]

@doctorjakeuro @UTSWUrology 2️⃣ next, Dr. Eric Li, resident from @NM_Urology, presents exciting work on the performance of an AI-derived digital pathology biomarker in radical prostatectomy patients from the PLCO trial

[Joshua Meeks @JoshMeeks]

Ever wonder why NMIBCs respond (or don't) to pembrolizumab? We did, too! Here is our spatial analysis comparing identifying stromal and epithelial signatures of response to IV and intravesical pembrolizumab.
https://t.co/Mb6tAZSPcL